1. Home
  2. SUNS vs SCYX Comparison

SUNS vs SCYX Comparison

Compare SUNS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunrise Realty Trust Inc.

SUNS

Sunrise Realty Trust Inc.

HOLD

Current Price

$8.32

Market Cap

126.3M

Sector

Real Estate

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.88

Market Cap

32.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUNS
SCYX
Founded
2023
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.3M
32.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SUNS
SCYX
Price
$8.32
$0.88
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$8.75
$3.00
AVG Volume (30 Days)
78.6K
318.1K
Earning Date
03-12-2026
03-04-2026
Dividend Yield
14.44%
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
$110.86
$90.24
Revenue Next Year
$9.41
N/A
P/E Ratio
$8.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.80
$0.57
52 Week High
$11.78
$1.29

Technical Indicators

Market Signals
Indicator
SUNS
SCYX
Relative Strength Index (RSI) 29.07 61.59
Support Level N/A $0.68
Resistance Level $9.69 $1.29
Average True Range (ATR) 0.28 0.06
MACD -0.11 0.01
Stochastic Oscillator 1.69 73.68

Price Performance

Historical Comparison
SUNS
SCYX

About SUNS Sunrise Realty Trust Inc.

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: